224 related articles for article (PubMed ID: 3104261)
1. Synergistic antitumor effects of BCG and monoclonal antibodies capable of inducing antibody-dependent cell-mediated cytotoxicity.
Komuta K; Kawase I; Ogura T; Masuno T; Yokota S; Hosoe S; Ikeda T; Shirasaka T; Kishimoto S
Jpn J Cancer Res; 1987 Feb; 78(2):185-92. PubMed ID: 3104261
[TBL] [Abstract][Full Text] [Related]
2. Murine tumor cell lysis by antibody-dependent macrophage-mediated cytotoxicity using syngeneic monoclonal antibodies.
Kawase I; Komuta K; Ogura T; Fujiwara H; Hamaoka T; Kishimoto S
Cancer Res; 1985 Apr; 45(4):1663-8. PubMed ID: 3978634
[TBL] [Abstract][Full Text] [Related]
3. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes.
Masui H; Moroyama T; Mendelsohn J
Cancer Res; 1986 Nov; 46(11):5592-8. PubMed ID: 3756906
[TBL] [Abstract][Full Text] [Related]
5. Effector mechanism in antitumor activity of monoclonal antibodies produced against an ascitic mouse mammary tumor.
Seto M; Takahashi T; Nakamura S; Saito M; Hara T; Nishizuka Y
Cancer Res; 1986 Apr; 46(4 Pt 2):2056-61. PubMed ID: 3004718
[TBL] [Abstract][Full Text] [Related]
6. In vivo antitumor effects of monoclonal antibodies with different immunoglobulin classes.
Seto M; Takahashi T; Nakamura S; Matsudaira Y; Nishizuka Y
Cancer Res; 1983 Oct; 43(10):4768-73. PubMed ID: 6192909
[TBL] [Abstract][Full Text] [Related]
7. Unusually efficient tumor cell lysis by human effectors of antibody-dependent cellular cytotoxicity mediated by monoclonal antibodies.
Christiaansen JE; Sears DW
Cancer Res; 1984 Sep; 44(9):3712-8. PubMed ID: 6744288
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo.
Drebin JA; Link VC; Greene MI
Oncogene; 1988 Apr; 2(4):387-94. PubMed ID: 2896329
[TBL] [Abstract][Full Text] [Related]
9. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.
van Ojik HH; Bevaart L; Dahle CE; Bakker A; Jansen MJ; van Vugt MJ; van de Winkel JG; Weiner GJ
Cancer Res; 2003 Sep; 63(17):5595-600. PubMed ID: 14500400
[TBL] [Abstract][Full Text] [Related]
10. Cytolytic interactions between murine macrophages, tumor cells, and monoclonal antibodies: characterization of lytic conditions and requirements for effector activation.
Johnson WJ; Steplewski Z; Matthews TJ; Hamilton TA; Koprowski H; Adams DO
J Immunol; 1986 Jun; 136(12):4704-13. PubMed ID: 3711663
[TBL] [Abstract][Full Text] [Related]
11. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
Hernandez-Ilizaliturri FJ; Jupudy V; Ostberg J; Oflazoglu E; Huberman A; Repasky E; Czuczman MS
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5866-73. PubMed ID: 14676108
[TBL] [Abstract][Full Text] [Related]
12. Enhanced cytotoxicity against colon carcinoma by combinations of noncompeting monoclonal antibodies to the 17-1A antigen.
Fogler WE; Klinger MR; Abraham KG; Gottlinger HG; Riethmuller G; Daddona PE
Cancer Res; 1988 Nov; 48(22):6303-8. PubMed ID: 2460221
[TBL] [Abstract][Full Text] [Related]
13. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
Shiloni E; Eisenthal A; Sachs D; Rosenberg SA
J Immunol; 1987 Mar; 138(6):1992-8. PubMed ID: 3493293
[TBL] [Abstract][Full Text] [Related]
14. Enhanced tumor growth and metastatic spread of an MH134 variant lacking a part of the MM antigen: a possible role of antibody-dependent cellular cytotoxicity in control of tumor growth and metastases.
Hara H; Kawase I; Komuta K; Masuno T; Kishimoto S
Int J Cancer; 1989 Jul; 44(1):137-42. PubMed ID: 2744883
[TBL] [Abstract][Full Text] [Related]
15. Effector characteristics of the IgG3 murine monoclonal antibody 113F1.
Weiner LM; Zarou CM; O'Brien J; Ring D
J Biol Response Mod; 1989 Jun; 8(3):227-37. PubMed ID: 2787391
[TBL] [Abstract][Full Text] [Related]
16. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
[TBL] [Abstract][Full Text] [Related]
17. Treatment of a murine B cell lymphoma with monoclonal antibodies and IL 2.
Berinstein N; Levy R
J Immunol; 1987 Aug; 139(3):971-6. PubMed ID: 3496394
[TBL] [Abstract][Full Text] [Related]
18. The ADCC capacity of macrophages from C3H/HeJ and A/J mice can be augmented by BCG.
Koren HS; Meltzer MS; Adams DO
J Immunol; 1981 Mar; 126(3):1013-5. PubMed ID: 7007498
[TBL] [Abstract][Full Text] [Related]
19. Antibody-mediated killing of human tumor cells by attached effector cells.
Hellström I; Garrigues U; Lavie E; Hellström KE
Cancer Res; 1988 Feb; 48(3):624-7. PubMed ID: 3335025
[TBL] [Abstract][Full Text] [Related]
20. Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages.
Nakajima H; Fujiwara H; Takai Y; Izumi Y; Sano S; Tsuchida T; Hamaoka T
J Immunol; 1985 Sep; 135(3):2199-205. PubMed ID: 3894520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]